Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle Safety Activities For BRINAVESS™ (Vernakalant

Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle 
Safety Activities For BRINAVESS™ (Vernakalant Intravenous) 
NASDAQ: CRME TSX: COM 
VANCOUVER, Feb. 4, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: 
COM) today announced the selection of Quintiles to provide comprehensive 
post-marketing lifecycle safety and global regulatory affairs services for 
BRINAVESS™. Quintiles, the world's leading provider of biopharmaceutical 
services, will begin providing these services effective immediately as 
Cardiome continues to prepare for the anticipated transfer of BRINAVESS(TM) 
from Merck to Cardiome. 
"We are very pleased to begin our partnership with Quintiles during the 
pending return of global rights for the intravenous (IV) and oral formulations 
of vernakalant to Cardiome," stated William Hunter, M.D., interim CEO of 
Cardiome. "Finding a highly capable service provider to deliver operational 
regulatory and pharmacovigilance support was a key priority to effectively and 
expeditiously transfer the registered marketing authorizations from Merck to 
Cardiome. We believe that Quintiles' global reach and extensive expertise in 
these areas will help facilitate a seamless worldwide transition." 
In September 2012, Merck informed Cardiome that Merck (through two of its 
subsidiaries) would return the global marketing and development rights for 
both the intravenous and oral formulations of vernakalant to Cardiome. 
Vernakalant IV is marketed under the brand name BRINAVESS(TM). BRINAVESS(TM) 
has received approval in the European Union and certain other markets 
worldwide for the rapid conversion of recent onset atrial fibrillation (AF) to 
sinus rhythm in adults: for non-surgery patients with AF of seven days or less 
and for post-cardiac surgery patients with AF of three days or less. 
Vernakalant IV is not approved for use in the United States or Canada. 
About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical 
company dedicated to the discovery, development and commercialization of new 
therapies that will improve the health of patients around the world. Cardiome 
has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe 
and other territories for the rapid conversion of recent onset atrial 
fibrillation to sinus rhythm in adults. 
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock 
Exchange (COM). For more information, please visit our web site at 
www.cardiome.com. 
Forward-Looking Statement Disclaimer 
Certain statements in this press release contain forward-looking statements 
within the meaning of the Private Securities Litigation Reform Act of 1995 or 
forward-looking information under applicable Canadian securities legislation 
that may not be based on historical fact, including without limitation 
statements containing the words "believe", "may", "plan", "will", "estimate", 
"continue", "anticipate", "intend", "expect" and similar expressions. Such 
forward-looking statements or information involve known and unknown risks, 
uncertainties and other factors that may cause our actual results, events or 
developments, or industry results, to be materially different from any future 
results, events or developments expressed or implied by such forward-looking 
statements or information. Risks, uncertainties and factors that could cause 
such actual events or results expressed or implied by such forward-looking 
statements and information to differ materially from any future events or 
results expressed or implied by such statements and information include, but 
are not limited to, the risks, uncertainties and factors related to the fact 
that: we, together with our collaborative partner, may not be able to 
successfully develop all or any of our current or future products and may not 
be able toobtain regulatory approval in targeted indications for our current 
or future products in all markets; we may not achieve or maintain 
profitability; our future operating results are uncertain and likely to 
fluctuate; we may not be able to raise additional capital as and when 
required; we depend on our collaborative partner to perform their obligations 
under licensing or other collaborative agreements; we may not be successful in 
establishing additional corporate collaborations or licensing arrangements; we 
may not be able to establish marketing and sales capabilities and the costs of 
launching our products may be greater than anticipated; any of our products 
that obtain regulatory approval will be subject to extensive post-market 
regulation that may affect sales, marketing and profitability; any of our 
products that are successfully developed may not achieve market acceptance; we 
rely on third parties for the continued supply and manufacture of our products 
and have no experience in commercial manufacturing; we may face unknown risks 
related to intellectual property matters, including with respect to our 
ability to protect our intellectual property; we face increased competition 
from pharmaceutical and biotechnology companies; and other factors as 
described in detail in our filings with the Securities and Exchange Commission 
available at www.sec.gov and the Canadian securities regulatory authorities at 
www.sedar.com. Given these risks, uncertainties and factors, you are 
cautioned not to place undue reliance on such forward-looking statements and 
information, which are qualified in their entirety by this cautionary 
statement. All forward-looking statements and information made herein are 
based on our current expectations and we undertake no obligation to revise or 
update such forward-looking statements and information to reflect subsequent 
events or circumstances, except as required by law. 
Cardiome Investor Relations (604) 676-6993 or Toll Free: 1-800-330-9928 
Email:ir@cardiome.com 
SOURCE: Cardiome Pharma Corp. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/February2013/04/c2958.html 
CO: Cardiome Pharma Corp.
ST: British Columbia
NI: MTC  
-0- Feb/04/2013 21:15 GMT